Risk factors

Vor Biopharma (VOR) risk factors

Item 1A of every Vor Biopharma Inc. 10-K on file, and what changed from one year to the next.

Open VOR in Gloomberb →
  • FY2025 10-K risk factors

    85 risks, 16 new, 28 dropped, 26 reworded since the prior year. Vor Biopharma expanded its portfolio by in-licensing telitacicept from RemeGen, creating new operational and regulatory dependencies on third-party trials in China.

    Filed Mar 30, 2026
  • FY2024 10-K risk factors

    97 risks. Vor Biopharma faces significant net losses, an accumulated deficit of $457.0 million, and substantial doubt about its going concern status.

    Filed Mar 20, 2025